Recent Updates — MBRX

Moleculin Biotech completed patient dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin combined with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia. The fully treated, randomized, double-blind Part A population consists of n=90 patients, providing a balanced representation between those who failed intensive chemotherapy and venetoclax-based regimens. Comprehensive data from this cohort is expected in the first quarter of 2027 to support dose selection for Part B of the trial. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing therapeutic candidates for hard-to-treat tumors.

Moleculin Biotech's board approved a one-for-twenty (1:20) reverse stock split of its common stock, following shareholder authorization at the annual meeting on October 9, 2026. The amendment to the certificate of incorporation was filed with the Delaware Secretary of State and will become effective at 12:01 a.m. Eastern Time on October 20, 2026. Trading on the Nasdaq Capital Market will resume on a post-split basis under ticker MBRX with a new CUSIP number. Outstanding shares will decrease from approximately 20.9 million to roughly 1.05 million, while authorized shares remain at 500 million. Fractional shares will be cashed out based on the average closing price over the preceding five trading days. Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing therapeutic candidates for hard-to-treat tumors and viruses.

Moleculin Biotech stockholders approved an amendment to the Certificate of Incorporation granting the Board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-20, determined by the Board prior to the one-year anniversary. Conversely, shareholders rejected an amendment to eliminate supermajority voting requirements for future Charter amendments. The meeting also saw approval of the 2024 Equity Plan share increase and director elections. Moleculin Biotech is a clinical-stage biopharmaceutical company focused on developing therapies for cancer.

Moleculin Biotech announced on September 29, 2026, the completion of enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin combined with cytarabine for relapsed or refractory acute myeloid leukemia. The company enrolled 89 subjects and remains on track for a comprehensive data readout in the first quarter of 2027. Moleculin is a clinical-stage pharmaceutical company developing therapeutic candidates for hard-to-treat tumors.